Immunoengineering with biomaterials for enhanced cancer immunotherapy

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 10, Issue 4, 2018, Pages

  Xie, Yu Qing ^a   Wei, Lixia ^a   Tang, Li ^a  

^a EPFL   (Switzerland)

Author keywords

adoptive cell transfer; agonistic antibodies; biomaterials; cancer immunotherapy; combination therapy; immune checkpoint inhibitor; immuno gene therapy; immunoengineering; immunomodulators

Indexed keywords

ANTIBODIES; BIOMATERIALS; GENE THERAPY; IMPLANTS (SURGICAL); MEDICAL NANOTECHNOLOGY; SURGERY;

CANCER IMMUNOTHERAPY; CELL TRANSFER; COMBINATION THERAPY; IMMUNE CHECKPOINT INHIBITOR; IMMUNOENGINEERING; IMMUNOMODULATORS;

DISEASES;

ANTIBODY; ANTINEOPLASTIC AGENT; BIOMATERIAL; CHECKPOINT BLOCKADE ANTIBODY; CYTOKINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; PATTERN RECOGNITION RECEPTOR; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BIOENGINEERING; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL THERAPY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOENGINEERING; IMMUNOMODULATION; IMMUNOSTIMULATION; MALIGNANT NEOPLASM; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTHERMAL THERAPY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT; ANIMAL; IMMUNOTHERAPY; MOUSE; NEOPLASM; PROTEIN ENGINEERING;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES; BIOCOMPATIBLE MATERIALS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; PROTEIN ENGINEERING;

EID: 85040685205     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1506     Document Type: Review

References (183)

1. Abken, H. (2017). Driving CARs on the highway to solid cancer: Some considerations on the adoptive therapy with CAR T cells. Human Gene Therapy, 28, 1047–1060.
2. Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015). Big opportunities for small molecules in immuno-oncology. Nature Reviews. Drug Discovery, 14, 603–622.
3. Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011). FDA-approved poly(ethylene glycol)–protein conjugate drugs. Polymer Chemistry, 2, 1442–1448.
4. Aliperta, R., Welzel, P. B., Bergmann, R., Freudenberg, U., Berndt, N., Feldmann, A., … Bachmann, M. P. (2017). Cryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy. Scientific Reports, 7, 42855.
5. Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., … Pittet, M. J. (2017). In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy. Science Translational Medicine, 9, eaal3604.
6. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., … Rosenberg, S. A. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17, 2105–2116.
7. Banga, R. J., Meckes, B., Narayan, S. P., Sprangers, A. J., Nguyen, S. T., & Mirkin, C. A. (2017). Cross-linked Micellar spherical nucleic acids from Thermoresponsive templates. Journal of the American Chemical Society, 139, 4278–4281.
8. Bourquin, C., Anz, D., Zwiorek, K., Lanz, A.-L., Fuchs, S., Weigel, S., … Endres, S. (2008). Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient Antitumoral immunity. Journal of Immunology, 181, 2990–2998.
9. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., … Robert, C. (2016). Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews. Clinical Oncology, 13, 473–486.
10. Bruns, H., Bessell, C., Varela, J. C., Haupt, C., Fang, J., Pasemann, S., … Schütz, C. (2015). CD47 enhances in vivo functionality of artificial antigen-presenting cells. Clinical Cancer Research, 21, 2075–2083.
11. Butler, M. O., & Hirano, N. (2014). Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunological Reviews, 257, 191–209.
12. Chen, J., Gao, P., Yuan, S., Li, R., Ni, A., Chu, L., … Duan, Y. (2016). Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy. ACS Nano, 10, 11548–11560.
13. Chen, M., Ouyang, H., Zhou, S., Li, J., & Ye, Y. (2014). PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses. Cellular Immunology, 287, 91–99.
14. Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016). Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nature Communications, 7, 13193.
15. Chen, Y., Xia, R., Huang, Y., Zhao, W., Li, J., Zhang, X., … Li, S. (2016). An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nature Communications, 7, 13443.
16. Choi, J., Kim, H.-Y., EJ, J., Hung, J., Park, J., Chung, H.-K., … Choi, E. K. (2012). Use of macrophages to delivery therapeutic and imaging contrast agents to tumors. Biomaterials, 33, 4195–4203.
17. Chu, D., Gao, J., & Wang, Z. (2015). Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano, 9, 11800–11811.
18. Clinical Trial. (2012). Clinical trial of a therapeutic vaccine with NY-ESO-1 in combination with the adjuvant monophosphoryl lipid A (MPLA) (Identification No. NCT01584115). Retrieved from http://clinicaltrials.gov/ct2
19. Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016). Neutrophils in cancer: Neutral no more. Nature Reviews. Cancer, 16, 431–446.
20. Coley, W. B. (1893). The treatment of Malignat tumors by repeated inoculations of erysipelas. The American Journal of the Medical Sciences, 105, 487–510.
21. Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., … Gajewski, T. F. (2015). Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports, 11, 1018–1030.
22. Crittenden, M., Kohrt, H., Levy, R., Jones, J., Camphausen, K., Dicker, A., … Formenti, S. (2015). Current clinical trials testing combinations of immunotherapy and radiation. Seminars in Radiation Oncology, 25, 54–64.
23. Cubillos-Ruiz, J. R., Engle, X., Scarlett, U. K., Martinez, D., Barber, A., Elgueta, R., … Conejo-Garcia, J. R. (2009). Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. The Journal of Clinical Investigation, 119, 2231–2244.
24. Da Silva, C. G., Rueda, F., Löwik, C. W., Ossendorp, F., & Cruz, L. J. (2016). Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials, 83, 308–320.
25. De Palma, M., Mazzieri, R., Politi, L. S., Pucci, F., Zonari, E., Sitia, G., … Naldini, L. (2008). Tumor-targeted interferon-α delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell, 14, 299–311.
26. De Vos, J., Devoogdt, N., Lahoutte, T., & Muyldermans, S. (2013). Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: Adjusting the bullet to its target. Expert Opinion on Biological Therapy, 13, 1149–1160.
27. Dendritic Cell Activating Scaffold in Melanoma. (2017). Dendritic cell activating scaffold in melanoma (Identification No. NCT01753089). Retrieved from http://clinicaltrials.gov/ct2
28. Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., … Lowman, H. B. (2013). Tumor-specific activation of an EGFR-targeting Probody enhances therapeutic index. Science Translational Medicine, 5, 207ra144.
29. Duan, X., Chan, C., Guo, N., Han, W., Weichselbaum, R. R., & Lin, W. (2016). Photodynamic therapy mediated by nontoxic Core-Shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and Antimetastatic effect on breast cancer. Journal of the American Chemical Society, 138, 16686–16695.
30. Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martinez-Forero, I., Perez-Gracia, J. L., … Melero, I. (2010). Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunology, Immunotherapy, 59, 1223–1233.
31. Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011). Use of defined TLR ligands as adjuvants within human vaccines. Immunological Reviews, 239, 178–196.
32. Ebner, D. K., Tinganelli, W., Helm, A., Bisio, A., Yamada, S., Kamada, T., … Durante, M. (2017). The immunoregulatory potential of particle radiation in cancer therapy. Frontiers in Immunology, 8, 1–8.
33. Eggermont, L. J., Paulis, L. E., Tel, J., & Figdor, C. G. (2014). Towards efficient cancer immunotherapy: Advances in developing artificial antigen-presenting cells. Trends in Biotechnology, 32, 456–465.
34. Erster, O., Thomas, J. M., Hamzah, J., Jabaiah, A. M., Getz, J. A., Schoep, T. D., … Daugherty, P. S. (2012). Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. Journal of Controlled Release, 161, 804–812.
35. Escobar, G., Moi, D., Ranghetti, A., Ozkal-Baydin, P., Squadrito, M. L., Kajaste-Rudnitski, A., … Naldini, L. (2014). Genetic engineering of hematopoiesis for targeted IFN- delivery inhibits breast cancer progression. Science Translational Medicine, 6, 217ra3.
36. Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., … Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature, 543, 113–117.
37. Fadel, T. R., Sharp, F. A., Vudattu, N., Ragheb, R., Garyu, J., Kim, D., … Fahmy, T. M. (2014). A carbon nanotube–polymer composite for T-cell therapy. Nature Nanotechnology, 9, 639–647.
38. Fan, Y., & Moon, J. (2015). Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy. Vaccine, 3, 662–685.
39. Fang, R. H., & Zhang, L. (2016). Nanoparticle-based modulation of the immune system. Annu Rev Chem Biomol Eng, 7, 305–326.
40. Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016). Cancer immunotherapy: The beginning of the end of cancer? BMC Medicine, 14, 73.
41. Fesnak, A. D., June, C. H., & Levine, B. L. (2016). Engineered T cells: The promise and challenges of cancer immunotherapy. Nature Reviews. Cancer, 16, 566–581.
42. Fisher, J. P. H., Yan, M., Heuijerjans, J., Carter, L., Abolhassani, A., Frosch, J., … Anderson, J. (2014). Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells. Clinical Cancer Research, 20, 5720–5732.
43. Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., … Li, M. O. (2014). The cellular and molecular origin of tumor-associated macrophages. Science, 344, 921–925.
44. Gammon, J. M., Dold, N. M., & Jewell, C. M. (2016). Improving the clinical impact of biomaterials in cancer immunotherapy. Oncotarget, 7, 15421–15443.
45. Gangadhar, T. C., & Vonderheide, R. H. (2014). Mitigating the toxic effects of anticancer immunotherapy. Nature Reviews. Clinical Oncology, 11, 91–99.
46. Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews. Cancer, 11, 123–134.
47. Genard, G., Lucas, S., & Michiels, C. (2017). Reprogramming of tumor-associated macrophages with anticancer therapies: Radiotherapy versus chemo- and immunotherapies. Frontiers in Immunology, 8, 828.
48. Goldberg, M. S. (2015). Immunoengineering: How nanotechnology can enhance cancer immunotherapy. Cell, 161, 201–204.
49. Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., … Dranoff, G. (2017). Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature Reviews. Cancer, 17, 286–301.
50. Graciotti, M., Berti, C., Klok, H.-A., & Kandalaft, L. (2017). The era of bioengineering: How will this affect the next generation of cancer immunotherapy? Journal of Translational Medicine, 15, 142.
51. Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., … Schreiber, R. D. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 515, 577–581.
52. Hammink, R., Mandal, S., Eggermont, L. J., Nooteboom, M., Willems, P. H. G. M., Tel, J., … Blank, K. G. (2017). Controlling T-cell activation with synthetic dendritic cells using the Multivalency effect. ACS Omega, 2, 937–945.
53. Hasan, A. N., Selvakumar, A., Shabrova, E., Liu, X. R., Afridi, F., Heller, G., … O'Reilly, R. J. (2016). Soluble and membrane-bound interleukin (IL)-15 R alpha/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections. Clinical and Experimental Immunology, 186, 249–265.
54. Hashimoto-Tane, A., & Saito, T. (2016). Dynamic regulation of TCR-microclusters and the microsynapse for T cell activation. Frontiers in Immunology, 7, 1–8.
55. He, C., Duan, X., Guo, N., Chan, C., Poon, C., Weichselbaum, R. R., & Lin, W. (2016). Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nature Communications, 7, 12499.
56. Heinis, C., Rutherford, T., Freund, S., & Winter, G. (2009). Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nature Chemical Biology, 5, 502–507.
57. Hendrickx, R., Stichling, N., Koelen, J., Kuryk, L., Lipiec, A., & Greber, U. F. (2014). Innate immunity to adenovirus. Human Gene Therapy, 25, 265–284.
58. Hernandez-Alcoceba, R., Poutou, J., Ballesteros-Briones, M. C., & Smerdou, C. (2016). Gene therapy approaches against cancer using in vivo and ex vivo gene transfer of interleukin-12. Immunotherapy, 8, 179–198.
59. Hickey, J. W., Vicente, F. P., Howard, G. P., Mao, H.-Q., & Schneck, J. P. (2017). Biologically inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for immunomodulation. Nano Letters, 17, 7045–7054.
60. Ho, P. C., Bihuniak, J. D., MacIntyre, A. N., Staron, M., Liu, X., Amezquita, R., … Phosphoenolpyruvate, I. (2015). A metabolic checkpoint of anti-tumor T cell responses. Cell, 162, 1217–1228.
61. Ho, P. C., Kaech, S. M., & Reenergizing, T. (2017). Cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries. Current Opinion in Immunology, 46, 38–44.
62. Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell, 157, 1262–1278.
63. Huang, B., Abraham, W. D., Zheng, Y., Bustamante Lopez, S. C., Luo, S. S., & Irvine, D. J. (2015). Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Science Translational Medicine, 7, 291ra94.
64. Huang, Z., Gan, J., Long, Z., Guo, G., Shi, X., Wang, C., … Dong, L. (2016). Targeted delivery of let-7b to reprogramme tumor-associated macrophages and tumor infiltrating dendritic cells for tumor rejection. Biomaterials, 90, 72–84.
65. Huang, Z., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2012). Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. Journal of Controlled Release, 158, 286–292.
66. Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015). Synthetic nanoparticles for vaccines and immunotherapy. Chemical Reviews, 115, 11109–11146.
67. Jiang, P. S., CF, Y., Yen, C. Y., Woo, C. W., Lo, S. H., Huang, Y. K., … Chiang, C. S. (2015). Irradiation enhances the ability of monocytes as nanoparticle carrier for cancer therapy. PLoS ONE, 10, e0139043.
68. Jones, R. B., Mueller, S., Kumari, S., Vrbanac, V., Genel, S., Tager, A. M., … Irvine, D. J. (2017). Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials, 117, 44–53.
69. Kalos, M., June, C. H., & Adoptive, T. (2013). Cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity, 39, 49–60.
70. Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015). Oncolytic viruses: A new class of immunotherapy drugs. Nature Reviews. Drug Discovery, 14, 642–662.
71. Kiefer, J. D., & Neri, D. (2016). Immunocytokines and bispecific antibodies: Two complementary strategies for the selective activation of immune cells at the tumor site. Immunological Reviews, 270, 178–192.
72. Kleinovink, J. W., Fransen, M. F., Löwik, C. W., & Ossendorp, F. (2017). Photodynamic-immune checkpoint therapy eradicates local and distant tumors by CD8+ T cells. Cancer Immunology Research, 5, 832–838.
73. Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., … Beckhove, P. (2013). Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell, 24, 589–602.
74. Kolaczkowska, E., & Kubes, P. (2013). Neutrophil recruitment and function in health and inflammation. Nature Reviews. Immunology, 13, 159–175.
75. Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R., & Mooney, D. J. (2017). Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Advanced Biosystems, 1, 1600013.
76. Koshy, S. T., & Mooney, D. J. (2016). Biomaterials for enhancing anti-cancer immunity. Current Opinion in Biotechnology, 40, 1–8.
77. Kosmides, A. K., Meyer, R. A., Hickey, J. W., Aje, K., Cheung, K. N., Green, J. J., & Schneck, J. P. (2017). Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials, 118, 16–26.
78. Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., … Sahin, U. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 534, 396–401.
79. Krieg, A. M. (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27, 161–167.
80. Kunz-Schughart, L. A., Dubrovska, A., Peitzsch, C., Ewe, A., Aigner, A., Schellenburg, S., … Pokhrel, S. (2017). Nanoparticles for radiooncology: Mission, vision, challenges. Biomaterials, 120, 155–184.
81. Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013). Localized immunotherapy via liposome-anchored anti- CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Research, 73, 1547–1558.
82. Kwong, B., Liu, H., & Irvine, D. J. (2011). Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials, 32, 5134–5147.
83. Lambert, L. H., Goebrecht, G. K. E., De Leo, S. E., O'Connor, R. S., Nunez-Cruz, S., De Li, T., … Kam, L. C. (2017). Improving T cell expansion with a soft touch. Nano Letters, 17, 821–826.
84. Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014). Interleukin 12: Still a promising candidate for tumor immunotherapy? Cancer Immunology, Immunotherapy, 63, 419–435.
85. Lee, K., Yi, Y., & Yu, Y. (2016). Remote control of T cell activation using magnetic Janus particles. Angewandte Chemie International Edition, 55, 7384–7387.
86. Lei, C., Liu, P., Chen, B., Mao, Y., Engelmann, H., Shin, Y., … Hellstrom, K. E. (2010). Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. Journal of the American Chemical Society, 132, 6906–6907.
87. Li, H., Sun, Y., Chen, D., Zhao, H., Zhao, M., Zhu, X., … Li, W. (2015). Synergistic anti-tumor therapy by a comb-like multifunctional antibody nanoarray with exceptionally potent activity. Scientific Reports, 5, 15712.
88. Li, S. Y., Liu, Y., CF, X., Shen, S., Sun, R., XJ, D., … Wang, J. (2015). Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. Journal of Controlled Release, 231, 17–28.
89. Li, Y., Fang, M., Zhang, J., Wang, J., Song, Y., Shi, J., … Wang, L. (2016). Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology, 5, e1074374.
90. Liang, X., Luo, M., Wei, X., Ma, C., Yang, Y., & Shao, B. (2016). A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy. Oncotarget, 7, 52207–52217.
91. Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014). Going viral with cancer immunotherapy. Nature Reviews. Cancer, 14, 559–567.
92. Liu, H., Kwong, B., & Irvine, D. J. (2011). Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy. Angewandte Chemie International Edition, 50, 7052–7055.
93. Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., … Irvine, D. J. (2014). Structure-based programming of lymph-node targeting in molecular vaccines. Nature, 507, 519–522.
94. Liu, X., Gao, X., Zheng, S., Wang, B., Li, Y., Zhao, C., … Wei, Y. (2017). Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 13, 1993–2004.
95. Lu, K., He, C., Guo, N., Chan, C., Ni, K., Weichselbaum, R. R., & Lin, W. (2016). Chlorin-based Nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy. Journal of the American Chemical Society, 138, 12502–12510.
96. Lühmann, T., Schmidt, M., Leiske, M. N., Spieler, V., Majdanski, T. C., Grube, M., … Meinel, L. (2017). Site-specific POxylation of Interleukin-4. ACS Biomaterials Science & Engineering, 3, 304–312.
97. Ma, X., Hui, H., Jin, Y., Dong, D., Liang, X., Yang, X., … Tian, J. (2016). Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation. Biomaterials, 87, 46–56.
98. Martin-Liberal, J., Ochoa de Olza, M., Hierro, C., Gros, A., Rodon, J., & Tabernero, J. (2017). The expanding role of immunotherapy. Cancer Treatment Reviews, 54, 74–86.
99. Mascia, F., Lam, G., Keith, C., Garber, C., Steinberg, S. M., Kohn, E., & Yuspa, S. H. (2013). Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Science Translational Medicine, 5, 199ra110.
100. Meir, R., Shamalov, K., Betzer, O., Motiei, M., Horovitz-Fried, M., Yehuda, R., … Cohen, C. J. (2015). Nanomedicine for cancer immunotherapy: Tracking cancer-specific T-cells in vivo with gold nanoparticles and CT imaging. ACS Nano, 9, 6363–6372.
101. Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015). Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews. Cancer, 15, 457–472.
102. Miao, L., Li, J., Liu, Q., Feng, R., Das, M., Lin, C. M., … Huang, L. (2017). Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer. ACS Nano, 11, 8690–8706.
103. Min, Y., Roche, K. C., Tian, S., Eblan, M. J., McKinnon, K. P., Caster, J. M., … Wang, A. Z. (2017). Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nature Nanotechnology, 12, 877–882.
104. Mirsoian, A., Bouchlaka, M. N., Sckisel, G. D., Chen, M., Pai, C.-C. S., Maverakis, E., … Murphy, W. J. (2014). Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. The Journal of Experimental Medicine, 211, 2373–2383.
105. Mishra, D. K., Balekar, N., & Mishra, P. K. (2017). Nanoengineered strategies for siRNA delivery: From target assessment to cancer therapeutic efficacy. Drug Delivery and Translational Research, 7, 346–358.
106. Monette, A., Ceccaldi, C., Assaad, E., Lerouge, S., & Lapointe, R. (2016). Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies. Biomaterials, 75, 237–249.
107. Moran, A. E., Kovacsovics-Bankowski, M., & Weinberg, A. D. (2013). The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Current Opinion in Immunology, 25, 230–237.
108. Morrissey, K., Yuraszeck, T., Li, C. C., Zhang, Y., & Kasichayanula, S. (2016). Immunotherapy and novel combinations in oncology: Current landscape, challenges, and opportunities. Clinical and Translational Science, 9, 89–104.
109. Nagarsheth, N., Wicha, M. S., & Zou, W. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews. Immunology, 17, 559–572.
110. Nemeth, B. T., Varga, Z. V., WJ, W., & Pacher, P. (2016). Trastuzumab cardiotoxicity: From clinical trials to experimental studies. British Journal of Pharmacology, 174, 3727–3748.
111. Ngwa, W., Boateng, F., Kumar, R., Irvine, D. J., Formenti, S., Ngoma, T., … Hesser, J. (2017). Smart radiation therapy biomaterials. International Journal of Radiation Oncology, Biology, Physics, 97, 624–637.
112. Nuhn, L., Vanparijs, N., De Beuckelaer, A., Lybaert, L., Verstraete, G., Deswarte, K., … De Geest, B. G. (2016). pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proceedings of the National Academy of Sciences, 113, 8098–8103.
113. O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013). The history of toll-like receptors — Redefining innate immunity. Nature Reviews. Immunology, 13, 453–460.
114. Owens, B. (2017). Faster, deeper, smaller—The rise of antibody-like scaffolds. Nature Biotechnology, 35, 602–603.
115. Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., … Fahmy, T. M. (2012). Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nature Materials, 11, 895–905.
116. Pellegrini, M., Mak, T. W., & Ohashi, P. S. (2010). Fighting cancers from within: Augmenting tumor immunity with cytokine therapy. Trends in Pharmacological Sciences, 31, 356–363.
117. Perica, K., Bieler, J. G., Schütz, C., Varela, J. C., Douglass, J., Skora, A., … Schneck, J. P. (2015). Enrichment and expansion with Nanoscale artificial antigen presenting cells for adoptive immunotherapy. ACS Nano, 9, 6861–6871.
118. Perica, K., De León Medero, A., Durai, M., Chiu, Y. L., Bieler, J. G., Sibener, L., … Schneck, J. (2014). Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine: Nanotechnology, Biology and Medicine, 10, 119–129.
119. Pinelli, D. F., & Ford, M. L. (2015). Novel insights into {anti-CD40/CD154} immunotherapy in transplant tolerance. Immunotherapy, 7, 399–410.
120. Pollaro, L., Raghunathan, S., Morales-Sanfrutos, J., Angelini, A., Kontos, S., & Heinis, C. (2015). Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors. Molecular Cancer Therapeutics, 14, 151–161.
121. Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015). Immune checkpoint blockade in cancer therapy. Journal of Clinical Oncology, 33, 1974–1982.
122. Poust, J. C., Woolery, J. E., & Green, M. R. (2013). Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anti-Cancer Drugs, 24, 1–13.
123. Qi, Y., & Chilkoti, A. (2015). Protein-polymer conjugation-moving beyond PEGylation. Current Opinion in Chemical Biology, 28, 181–193.
124. Qin, D.-Y., Huang, Y., Li, D., Wang, Y.-S., Wang, W., & Wei, Y.-Q. (2016). Paralleled comparison of vectors for the generation of CAR-T cells. Anti-Cancer Drugs, 27, 711–722.
125. Qiu, H., Min, Y., Rodgers, Z., Zhang, L., & Wang, A. Z. (2017). Nanomedicine approaches to improve cancer immunotherapy. WIREs Nanomedicine and Nanobiotechnology, 9, e1456.
126. Radovic-Moreno, A. F., Chernyak, N., Mader, C. C., Nallagatla, S., Kang, R. S., Hao, L., … Gryaznov, S. M. (2015). Immunomodulatory spherical nucleic acids. Proceedings of the National Academy of Sciences, 112, 3892–3897.
127. Rahimian, S., Fransen, M. F., Kleinovink, J. W., Amidi, M., Ossendorp, F., & Hennink, W. E. (2015). Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials, 61, 33–40.
128. Ribas, A., Hodi, F. S., Callahan, M. K., Konto, C., & Wolchok, J. D. (2013). Hepatotoxicity with combination of Vemurafenib and Ipilimumab. The New England Journal of Medicine, 368, 1365–1366.
129. Roberts, M. J., Bentley, M. D., & Harris, J. M. (2012). Chemistry for peptide and protein PEGylation. Advanced Drug Delivery Reviews, 64, 116–127.
130. Rosenberg, S. A. (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Journal of the American Medical Association, 271, 907–913.
131. Rosenberg, S. A. (2014). IL-2: The first effective immunotherapy for human cancer. Journal of Immunology, 192, 5451–5458.
132. Rüter, J., Antonia, S. J., Burris, H. A., Huhn, R. D., & Vonderheide, R. H. (2010). Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biology & Therapy, 10, 983–993.
133. Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews. Cancer, 12, 278–287.
134. Shekarian, T., Valsesia-Wittmann, S., Brody, J., Michallet, M. C., Depil, S., Caux, C., & Marabelle, A. (2017). Pattern recognition receptors: Immune targets to enhance cancer immunotherapy. Annals of Oncology, 28, 1756–1766.
135. Sheng, W. Y., & Huang, L. (2011). Cancer immunotherapy and nanomedicine. Pharmaceutical Research, 28, 200–214.
136. Shimoni, O., Postma, A., Yan, Y., Scott, A. M., Heath, J. K., Nice, E. C., … Caruso, F. (2012). Macromolecule functionalization of disulfide-bonded polymer hydrogel capsules and cancer cell targeting. ACS Nano, 6, 1463–1472.
137. Shirota, H., & Klinman, D. M. (2016). CpG oligodeoxynucleotides as adjuvants for clinical use. In Immunopotentiators in modern vaccines Academic Press (Cambridge, Massachusetts, United States). (2nd ed., pp. 163–198).
138. Siefert, A. L., Fahmy, T. M., & Kim, D. (2017). Artificial antigen-presenting cells for immunotherapies. Methods in Molecular Biology, 1530, 343–353.
139. Singh, A., & Peppas, N. A. (2014). Hydrogels and scaffolds for immunomodulation. Advanced Materials, 26, 6530–6541.
140. Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., … Stephan, M. T. (2017). Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. The Journal of Clinical Investigation, 127, 2176–2191.
141. Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., … Stephan, M. T. (2017). In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nature Nanotechnology, 12, 813–820.
142. Soleimani, A. H., Garg, S. M., Paiva, I. M., Vakili, M. R., Alshareef, A., Huang, Y. H., … Lavasanifar, A. (2017). Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma. Drug Delivery and Translational Research, 7, 571–581.
143. Sondak, V. K., Smalley, K. S. M., Kudchadkar, R., Grippon, S., & Kirkpatrick, P. (2011). Ipilimumab. Nature Reviews. Drug Discovery, 10, 411–412.
144. Song, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., … Zhang, Z. (2017). Tumor microenvironment responsive Nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy. Nano Letters, 17, 6366–6375.
145. Steel, J. C., Waldmann, T. A., & Morris, J. C. (2012). Interleukin-15 biology and its therapeutic implications in cancer. Trends in Pharmacological Sciences, 33, 35–41.
146. Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012). Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials, 33, 5776–5787.
147. Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2014). Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nature Biotechnology, 33, 97–101.
148. Sun, S.-C. (2017). The non-canonical NF-κB pathway in immunity and inflammation. Nature Reviews. Immunology, 17, 545–558.
149. Sun, W., Ji, W., Hu, Q., Yu, J., Wang, C., Qian, C., … Transformable, G. Z. (2016). DNA nanocarriers for plasma membrane targeted delivery of cytokine. Biomaterials, 96, 1–10.
150. Sun, W., Lu, Y., & Gu, Z. (2014). Advances in anticancer protein delivery using micro−/nanoparticles. Particle and Particle Systems Characterization, 31, 1204–1222.
151. Sun, X., Han, X., Xu, L., Gao, M., Xu, J., Yang, R., & Liu, Z. (2017). Surface-engineering of red blood cells as artificial antigen presenting cells promising for cancer immunotherapy. Small, 13. https://doi.org/10.1002/smll.201701864
152. Sunshine, J. C., & Green, J. J. (2013). Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine, 8, 1173–1189.
153. Swartz, M. A., Hirosue, S., & Hubbell, J. A. (2012). Engineering approaches to immunotherapy. Science Translational Medicine, 4, 148rv9.
154. Sze, D. Y., Reid, T. R., & Rose, S. C. (2013). Oncolytic virotherapy. Journal of Vascular and Interventional Radiology, 24, 1115–1122.
155. Tang, C., Wang, X., Soh, H., Seyedin, S., Cortez, M. A., Krishnan, S., … Welsh, J. W. (2014). Combining radiation and immunotherapy: A new systemic therapy for solid tumors? Cancer Immunology Research, 2, 831–838.
156. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., … Sznol, M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. The New England Journal of Medicine, 366, 2443–2454.
157. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug Delivery Reviews, 63, 131–135.
158. U.S. Food and Drug Administration. (2017, August 30). U.S. Food and Drug Administration, Center for Biologics Evaluation and Research [Approval Letter]. KYMRIAH, Novartis Pharmaceuticals Corporation.
159. van der Weijden, J., Paulis, L. E., Verdoes, M., van Hest, J. C. M., & Figdor, C. G. (2014). The right touch: Design of artificial antigen-presenting cells to stimulate the immune system. Chemical Science, 5, 3355.
160. Van Woensel, M., Mathivet, T., Wauthoz, N., Rosière, R., Garg, A. D., Agostinis, P., … De Vleeschouwer, S. (2017). Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Scientific Reports, 7, 1217.
161. Waldmann, T. A. (2003). Immunotherapy: Past, present and future. Nature Medicine, 9, 269–277.
162. Wang, C., Sun, W., Wright, G., Wang, A. Z., & Gu, Z. (2017). Inflammation-triggered cancer immunotherapy by programmed delivery of CpG and anti-PD1 antibody. Advanced Materials, 29, 8912–8920.
163. Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017). In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nature Biomedical Engineering, 1, Article number: 0011.
164. Wang, C., Xu, L., Liang, C., Xiang, J., Peng, R., & Liu, Z. (2014). Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Advanced Materials, 26, 8154–8162.
165. Wang, C., Ye, Y., Hochu, G. M., Sadeghifar, H., & Gu, Z. (2016). Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Letters, 16, 2334–2340.
166. Wang, Y., Lin, Y.-X., Qiao, S.-L., An, H.-W., Ma, Y., Qiao, Z.-Y., … Wang, H. (2017). Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials, 112, 153–163.
167. Wang, Z., Li, J., Cho, J., & Malik, A. B. (2014). Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nature Nanotechnology, 9, 204–210.
168. Warashina, S., Nakamura, T., Sato, Y., Fujiwara, Y., Hyodo, M., Hatakeyama, H., & Harashima, H. A. (2016). Lipid nanoparticle for the efficient delivery of siRNA to dendritic cells. Journal of Controlled Release, 225, 183–191.
169. Weiner, G. J. (2010). Rituximab: Mechanism of action. Seminars in Hematology, 47, 115–123.
170. Weiner, G. J. (2015). Building better monoclonal antibody-based therapeutics. Nature Reviews. Cancer, 15, 361–370.
171. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., … Sznol, M. (2013). Nivolumab plus Ipilimumab in advanced melanoma. The New England Journal of Medicine, 369, 122–133.
172. Wu, C. C. N., Hayashi, T., Takabayashi, K., Sabet, M., Smee, D. F., Guiney, D. D., … Carson, D. A. (2007). Immunotherapeutic activity of a conjugate of a toll-like receptor 7 ligand. Proceedings of the National Academy of Sciences, 104, 3990–3995.
173. Wu, J., Tang, C., & Yin, C. (2017). Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy. Acta Biomaterialia, 47, 81–90.
174. Xu, J., Xu, L., Wang, C., Yang, R., Zhuang, Q., Han, X., … Liu, Z. (2017). Near-infrared-triggered photodynamic therapy with multitasking Upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer. ACS Nano, 11, 4463–4474.
175. Xu, Z., Wang, Y., Zhang, L., & Huang, L. (2014). Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano, 8, 3636–3645.
176. Xue, J., Zhao, Z., Zhang, L., Xue, L., Shen, S., Wen, Y., … Zhang, C. (2017). Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nature Nanotechnology, 12, 692–700.
177. Yang, G., Xu, L., Chao, Y., Xu, J., Sun, X., Wu, Y., … Liu, Z. (2017). Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nature Communications, 8, 902.
178. Ye, Y., Wang, J., Hu, Q., Hochu, G. M., Xin, H., Wang, C., & Gu, Z. (2016). Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors. ACS Nano, 10, 8956–8963.
179. Zhang, L., Zhu, G., Mei, L., Wu, C., Qiu, L., Cui, C., … Tan, W. (2015). Self-Assembled DNA Immunonanoflowers as Multivalent CpG Nanoagents. ACS Applied Materials & Interfaces, 7, 24069–24074.
180. Zhang, Q., Wei, W., Wang, P., Zuo, L., Li, F., Xu, J., … Xie, H. (2017). Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T-cell-based anticancer therapy. ACS Nano, 11, 10724–10732.
181. Zheng, Y., Stephan, M. T., Gai, S. A., Abraham, W., Shearer, A., & Irvine, D. J. (2013). In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes. Journal of Controlled Release, 172, 426–435.
182. Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017). Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule Immunomodulators to internalizing or noninternalizing receptors. ACS Nano, 11, 3089–3100.
183. Zulfiqar, B., Mahroo, A., Nasir, K., Farooq, R. K., Jalal, N., Rashid, M. U., & Asghar, K. (2017). Nanomedicine and cancer immunotherapy: Focus on indoleamine 2,3-dioxygenase inhibitors. Onco Targets and Therapy, 10, 463–476.